Which multinational pharmaceutical company or local company produces Pemetinib?

Pemigatinib (Pemigatinib) is a targeted therapy drug targeting FGFR2 gene fusion or rearrangement. It is mainly used to treat advanced or metastatic cholangiocarcinoma. The drug was developed by Incyte Incyte in the United States. It is the world's first FGFR inhibitor approved by the U.S. FDA for the treatment of cholangiocarcinoma. It has good targeted efficacy and safety and has become a new treatment option for patients with cholangiocarcinoma.

IncyteAs the original drug developer of pemetinib, the company has always been committed to the innovative development of cancer-targeted drugs. In 2020, Incyte the company successfully promoted the approval of FDA for pemetinib, which marked that the drug has entered the forefront of the international tumor treatment field. IncyteThrough independent research and development and global promotion, it has promoted the launch and application of this innovative drug in many countries and regions.

In mainland China, the development and commercialization rights of pemetinib are handled by Innovent Biologics Holdings Co., Ltd. (Innovent Biologics). At the end of 2018, Innovent signed a cooperation agreement with Incyte and obtained the exclusive development and sales rights of pemetinib in mainland China, Hong Kong, Macau and Taiwan. Innovent Biologics actively carries out clinical trials and registration applications. After multiple rounds of approvals, pemetinib was officially approved for marketing in China in 2022, with the trade name "Dabotan®". This initiative not only enriches the treatment options for cholangiocarcinoma in China, but also provides patients with more high-quality drug options.

In addition, pemetinib is gradually entering the market in other parts of Asia. Taking Laos as an example, the local pharmaceutical company ASEAN Pharmaceuticals (TLPH) obtained the production and sales authorization for pemetinib and was successfully approved for marketing in 2024. The specification of pemetinib produced by ASEAN Pharmaceutical is 4.5mg*42 tablets. The price is relatively affordable and convenient for patients to obtain. This reflects the strategy of improving drug accessibility through localized production and sales of pemetinib in different regions.

In summary, pemetinib is produced by the United StatesIncyteDeveloped by the company, it is an important targeted anti-cancer drug. In the Chinese market, Innovent Biologics is responsible for its development and sales, promoting the domestic application of the drug; while in regions such as Laos, production and promotion are achieved through local pharmaceutical companies. When patients use pemetinib, they need to use the drug rationally according to their own condition and available drug channels under the guidance of a professional doctor to obtain the best therapeutic effect.

Reference materials:https://go.drugbank.com/drugs/DB15102